The stock of AnaptysBio Inc (NASDAQ:ANAB) last traded at $25.12, down -0.51% from the previous session.
ANAB stock price is now -12.31% away from the 50-day moving average and -9.62% away from the 200-day moving average. The market capitalization of the company currently stands at $764.36M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $55, H.C. Wainwright recently initiated with Buy rating for AnaptysBio Inc (NASDAQ: ANAB). On July 19, 2024, JP Morgan Upgraded its previous ‘Neutral’ rating to ‘Overweight’ on the stock increasing its target price from $29 to quote $69, while ‘Leerink Partners’ rates the stock as ‘Outperform’
In other news, Lizzul Paul F., Chief Medical Officer sold 1,500 shares of the company’s stock on Sep 23 ’24. The stock was sold for $58,005 at an average price of $38.67. Upon completion of the transaction, the Chief Medical Officer now directly owns 15,398 shares in the company, valued at $0.39 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 23 ’24, Officer PAUL F LIZZUL bought 1,500 shares of the business’s stock. A total of $58,005 was incurred on buying the stock at an average price of $38.67. A total of 14.63% of the company’s stock is owned by insiders.
During the past 12 months, AnaptysBio Inc has had a low of $13.36 and a high of $41.31. As of last week, the company has a debt-to-equity ratio of 4.35, a current ratio of 10.23, and a quick ratio of 10.23. The fifty day moving average price for ANAB is $28.8766 and a two-hundred day moving average price translates $27.779 for the stock.
The latest earnings results from AnaptysBio Inc (NASDAQ: ANAB) was released for 2024-09-30. The net profit margin was -289.75% and return on equity was -161.81% for ANAB. The company reported revenue of $30.02 million for the quarter, compared to $3.32 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 804.67 percent.
